Sermonix Pharmaceuticals https://validator.w3.org/feed/docs/rss2.html Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium Who is Elaine? Sermonix Pharmaceuticals to Host Oral Presentation on Vaginal and Sexual Health at RISE UP for Breast Cancer Conference The Elaine 3 Study The Elaine Study The Elaine 2 Study Sermonix Pharmaceuticals Announces E-Poster Presentation on I-SPY 2 Study of Neoadjuvant Lasofoxifene at St. Gallen International Breast Cancer Conference 2023 Sermonix Pharmaceuticals Announces MBC Alliance Membership, New ‘Discover ELAINE’ Website Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer EQUALS Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics Breast Cancer Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” Partners & Collaborations Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s Effects on Vaginal Atrophy in Postmenopausal Women Lasofoxifene Company Overview Posters & Presentations Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women’s Sexual Health Annual Meeting 2023 Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations Media Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene Homepage News Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast Cancer Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023 Contact Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium About Expanded Access Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, Demonstrates Promising Ki67 Suppression in Phase 2 I-SPY 2 Arm Evaluating Therapy in Neoadjuvant Breast Cancer Setting Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy